USPTO serial 79296944
B BRENUS PHARMA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 23, 2021
- Examiner
- BROWNE, LUCY E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with B BRENUS PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products for treating pathologies that are controllable or curable by stimulated immunological reaction from a patient, namely, through infectious or oncological diseases; Veterinary products, namely, veterinary preparations for treating pathologies that are controllable or curable by stimulated immunological reaction from an animal, namely, through infectious or oncological diseases; Chemical preparations for pharmaceutical purposes, namely, for treating pathologies that are controllable or curable by stimulated immunological reaction from the patient, namely, through infectious or oncological diseases; Biological preparations for medical or therapeutic purposes, namely, preparations for the treatment of pathologies that are controllable or curable by stimulated immunological reaction from the patient, namely, through infectious or oncological diseases; Biological preparations for veterinary purposes, namely, preparations for the treatment of pathologies that are controllable or curable by stimulated immunological reaction from the patient, namely, through infectious or oncological diseases; Pharmaceutical preparations, namely, immune system aids for use in human medicine; Diagnostic preparations for medical use; Diagnostic preparations for veterinary use; Immunostimulants under the pharmaceutical monopoly; medicines in the nature of vaccinal administrations for stimulating the immune system for use in human medicine; Serums under the pharmaceutical monopoly for medical purposes, namely, pharmaceutical serums for the treatment of the immune system; Biocellular preparations for therapeutic or medical purposes, namely, pharmaceutical preparations for the treatment of the immune system | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 24, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 6, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 12, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 11, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 23, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 23, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 11, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 7, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 7, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 23, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 18, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 18, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 3, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 3, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 3, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 3, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 3, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 5, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 4, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 4, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 30, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 9, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 9, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 24, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 23, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 23, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 3, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 30, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 29, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |